Dataset Information


Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.

ABSTRACT: Programmed cell death ligand 1 (PD-L1) is a transmembrane protein that is expressed on tumor cells that suppresses the T cell-mediated immune response. Therapies targeting the PD-L1 pathway promote anti-tumor immunity and have shown promising results in some types of cancers. However, the functional and therapeutic roles of PD-L1 in osteosarcoma remain largely unknown. In this study, we found that PD-L1 protein was expressed in osteosarcoma cell lines and tissue microarray of patient tumors. Tissue microarray immunohistochemistry analysis showed that the overall and five-year survival rates of patients with high levels of PD-L1 expression were significantly shorter than patients with low levels. High levels of PD-L1 expression were also associated with metastasis in osteosarcoma patients. Furthermore, we applied the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 system to target PD-L1 gene at the DNA level in osteosarcoma cell lines. We found that the expression of PD-L1 could be efficiently disrupted by CRISPR/Cas9 system and PD-L1 knockdown increased drug sensitivities for doxorubicin and paclitaxel. These results suggest that PD-L1 is an independent prognostic factor in osteosarcoma and that PD-L1 knockout by CRISPR/Cas9 may be a therapeutic approach for the treatment of osteosarcoma.


PROVIDER: S-EPMC5444742 | BioStudies | 2017-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC6219031 | BioStudies
2017-01-01 | S-EPMC5491359 | BioStudies
1000-01-01 | S-EPMC6036896 | BioStudies
2017-01-01 | S-EPMC5642642 | BioStudies
1000-01-01 | S-EPMC5522039 | BioStudies
2014-01-01 | S-EPMC3925108 | BioStudies
2020-01-01 | S-EPMC7016277 | BioStudies
2014-01-01 | S-EPMC4082476 | BioStudies
2018-01-01 | S-EPMC5855785 | BioStudies
2016-01-01 | S-EPMC5006919 | BioStudies